Atopic Dermatitis Management in Rural and Underserved Communities: Overcoming the Distance for Improved Dermatology Care

Released On
November 1, 2019

Expires On
October 31, 2020

Media Type

Completion Time
60 minutes


Atopic Dermatitis

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Rural Medical Education (RME) Collaborative and Postgraduate Institute for Medicine.


Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians and registered nurses who care for patients who reside in rural and underserved areas.

Program Overview

Atopic dermatitis is a chronic inflammatory skin disease that affects up to 10% of adults and 25% of children in the United States, and its prevalence is on the rise. Underrecognition and undertreatment of atopic dermatitis are common, leading to increased morbidity, poor quality of life, and rising healthcare costs. Patients in rural and underserved areas, where access to dermatology specialty care and follow-up are challenging, are particularly at risk for undertreatment. Given that primary care clinicians are often the sole provider of dermatology care and treatment in rural and underserved communities, this CME/CE program is designed to update these healthcare professionals about the latest advances in the recognition, diagnosis, and treatment of atopic dermatitis. Faculty will discuss guideline-recommended management strategies, insights into the pathogenesis of atopic dermatitis, and the impact of the disease on quality of life. Real-world patient experiences and strategies to overcome rural-specific barriers, including the use of teledermatology, will also be discussed.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe how to prepare clinical practice settings for telehealth adoption and implementation
  • Discuss the pathophysiology and immunologic factors associated with atopic dermatitis
  • Differentiate atopic dermatitis from other skin conditions
  • Integrate clinical data and guideline recommendations into individualized treatment decisions for patients with inadequately controlled atopic dermatitis



Elizabeth A. Kiracofe, MD

Board-Certified Dermatologist
Illinois Dermatology Institute
Chicago, IL


Peter A. Lio, MD

Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, IL

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosures of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Elizabeth A. Kiracofe, MD

  • Advisory Board: AbbVie, Inc. and Galderma

Peter A. Lio, MD

  • Consultant: AbbVie, Inc., Amyris, Inc., Dermira, Eli Lilly and Company, Exeltis, Franklin BioScience, Kiniksa Pharmaceuticals, Ltd., L’Oreal USA, Inc., LEO Laboratories, Ltd. (LEO Pharma), Odeza, LLC, Theraplex, TopMD, Inc., Unilever, and Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.)
  • Advisory Board: Altus Labs, Dermavant Sciences, Ltd., DermTap, Inc., Dermveda, gpower, Inc., IntraDerm Pharmaceuticals, Johnson & Johnson Consumer Products Company, Menlo Therapeutics, Micreos Human Health B.V., Modernizing Medicine, Inc., National Eczema Association, Realm Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi US Services, Inc., Syncere Skin Systems, UCB, Inc., and Verrica Pharmaceuticals Inc.
  • Speaker: La Roche-Posay Laboratoire Pharmaceutique, Pfizer, Inc., Pierre Fabre Dermatologie, Regeneron Pharmaceuticals, Inc., and Valeant Pharmaceuticals North America, LLC
  • Grant/Research Support : AbbVie, Inc., AOBiome, LLC, La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), and Regeneron Pharmaceuticals, Inc.
  • Stockholder: LearnHealth, Inc./LearnSkin, Medable, Inc., and Modernizing Medicine, Inc.

Planners and Managers

The PIM planners and managers have nothing to disclose. The RME Collaborative planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

To receive credit, participants must view the entire activity and complete the post-test and evaluation. Participants who receive a score of 75% or better will receive CME/CNE credit. A certificate of credit will be available for immediate download to those who successfully complete the post-test and evaluation.

For questions regarding this CME/CE activity, please contact: Emily DeMace by phone, 800-913-9370 ext 704, or email,

For questions about the certification of this activity, please visit

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC 2019. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.